“New” cardiovascular risk factors in patients with chronic kidney disease: Role of folic acid treatment

• Published in: Kidney international Vol. 67; no. S93; pp. S39 - S43
• Main Authors: Bayés, Beatriz, Pastor, Mari Cruz, Bonal, Jordi, Romero, Ramón
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2005; Elsevier Limited
• Subjects: C-Reactive Protein; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - epidemiology; Chronic Disease; Folic Acid - therapeutic use; hemodialysis; homocysteine; Homocysteine - blood; Humans; Kidney Diseases - complications; Kidney Diseases - drug therapy; lipid peroxidation; Lipid Peroxidation - drug effects; Risk Factors; homocysteine; hemodialysis; C-reactive protein; lipid peroxidation
• ISSN: 0085-2538; 0098-6577; 1523-1755
• DOI: 10.1111/j.1523-1755.2005.09309.x

“New” cardiovascular risk factors in patients with chronic kidney disease: Role of folic acid treatment. Cardiovascular disease (CVD) is the principal cause of mortality in patients with chronic renal disease undergoing hemodialysis. In addition to the CVD risk factors, a new hypothesis has recently been aroused related to “new” factors involved in the development of atherosclerosis in the uremic patient; worthwhile mentioning are the homocysteine, inflammation, and oxidative stress, among others. The potential utility of the folic acid in the hyperhomocysteinemia control is well known, although its mechanism of action, either as antioxidant or anti-inflammatory, has not been established. Our results confirm that the patients undergoing dialysis demonstrate hyperhomocysteinemia, an increased inflammatory status, and an increase of the lipid peroxidation markers. The administration of IV folinic acid induces a reduction of homocysteine levels subordinate to the inflammatory status of the patient. Additionally, although no inflammatory effects were shown, the results provide evidence for the antioxidant effect of IV folinic acid administration by reducing the lipid peroxidation marker levels. The statistic analysis demonstrates no correlation among the 3 markers, in spite of its higher levels in these particular patients. Homocysteine does not independently predict mortality in patients taking oral folic acid. Nevertheless, the PCR (an inflammation marker) and the antibody antioxidative-LDL (a lipidic peroxidation marker) show a good prediction of mortality at the 24-month follow-up analysis. The knowledge of these “new” CV risk factors, as well as the factors that influence them, could be useful to prevent the development of atherosclerosis in patients with chronic renal disease.